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Abstract 
Objective: The use of local anesthetics associated to vasoconstrictor agents in dentistry is thoroughly justified and 
is widely extended, but we cannot ignore the fact that anesthetic infiltration poses risk of complications throughout 
the dental treatment period.  The objective of the present review is to document the reported effects the use of the 
local anesthetics most widely employed in dentistry, with or without association to vasoconstrictor agents may have 
in patients with any sort of cardiopathy. 
Study Design: We have searched for randomized clinical trials on the assessment of the cardiovascular effects of 
local anesthetics used in dentistry, without limits as  regards age or sex, conducted in patients with any type of car-
diopathy which were published during the last decade and were index-linked in Cochrane, Embase and Medline.
Results: We have found six randomized clinical trials index-linked in Medline and Cochrane in the past ten years. 
These trials compare different types of anesthetics: lidocaine 2%, mepivacaine 2%, prilocaine 2% , associated or 
not to different vasoconstrictor concentrations such as adrenaline or felypressin. The cardiopathies affecting the pa-
tients included in the different trials range from hypertension, ischemic heart disease, arrythmias, chronic coronary 
disease to heart transplantation. 
Conclusions: The use of anesthetics associated to vasoconstrictor agents is justified  in the case of patients with 
cardiopathies (once we get over the period in which any type of dental manipulation is contraindicated) and in con-
trolled hypertensive patients. In any case, we must be very careful with the choice and execution of the anesthetic 
technique, being it possible to use a dose between 1.8 and 3.6 ml, on a general basis. Further studies are necessary 
to establish the effects of these drugs on severe hypertensive patients or in patients with other more advanced car-
diopathies.
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Introduction
The use of anesthetics associated to vasoconstrictor 
agents is justified in the clinical practice of dentistry: it 
delays the absorption of local anesthetics and increases 
safety as lower doses of anesthetic are required (which 
diminishes its potential toxic risk). The use of Catecho-
lamine type vasoconstrictors in certain patients is a con-
troversial issue, especially in the case of patients with 
cardiopathies and/or diabetes and more precisely in tho-
se with coronariopathies and severe hypertension (1). 
In order to avoid these risks associated with the use of 
catecholamines, researchers have focused their efforts in 
searching for vasoconstrictor agents with a different che-
mical structure. Nowadays, only felypressin is marketed 
in Spain (2-L-Phenylalanine-8-L-lysine-vasopressin). It 
could be an adequate alternative to catecholamine type 
vasoconstrictors in the following circumstances: cardio-
pathies and especially ischemic cardiopathies, patients 
with high plasma concentrations of endogenous cate-
cholamines (feochromocytoma) or thyroid hormones 
(primary or secondary hyperthyroidism), patients under 
treatment with substances susceptible of causing dange-
rous interactions with catecholamines  (beta blocking 
drugs, tricyclic antidepressants, MAOIs antidepressants, 
sympathomimetic drugs such as cocaine, etc) or allergy 
to vasoconstrictor agents themselves (2-4). 
One of the most delicate and risky actions throughout 
any type of dental treatment is anesthetic infiltration. If 
we consider as well the great number of pharmacologic 
effects infiltrated substances have (anesthetics themsel-
ves and the adrenergic vasoconstrictors used to increase 
biodisponibility and to reduce anesthetic toxicity), it is 
obvious that the specialist confronts a situation he must 
know and control thoroughly. This situation becomes 
even more delicate when the patient suffers from any 
cardiopathy.
Within the category of patients with cardiovascular pa-
thologies we include: 
- Hypertensive heart disease, which in turn comprises 
two varieties, namely, hypertensive urgency and hy-
pertensive emergency. The latter may pose a vital risk 
for the patient and it requires urgent parenteral hypo-
tension treatment (5). Stage A hypertension is observed 
in patients with levels > 180/110mmHg without organic 
damage or associated factors. Stage B hypertensive pa-
tients show some systemic associated risk factor (tobac-
coism, dyslipidemia, over 60 yrs or a previous history of 
vascular processes) with the exception of diabetes me-
llitus and no signs of cardiovascular affectation. Stage 
C patients suffer from cardiovascular diseases, organic 
damage and / or diabetes mellitus but do not show any 
other risk factors. 
- Ischemic heart disease: first of all, we must bear in 
mind the fact that patients who have suffered acute myo-
cardial infarction have a high risk of suffering a new 
infarction, and very often severe arrhythmias. Also, the 
risk of a second infarction during non cardiac surgery is 
known to reach 27% during the first months after infarc-
tion, 11% between months 3 and 6 and it drops to 5% 
from  month 6 onwards. As a result, dental treatment is 
not indicated up to 6 months after the episode of acute 
myocardial infarction (6, 7).
- Arrhythmias: arrhythmia is defined as any disorder of 
your heart rate or rhythm. As regards heart rate we may 
find two opposing situations, bradyarrhythmia (heart 
rate less than 60 beats per minute) and tachyarrhythmia 
(heart rate more than 100 beats per minute). In these pa-
tients preoperative evaluation must be detailed in order 
to assess the origin of the arrhythmia, the need of prior 
stabilization of the patient before the treatment, the risk 
of arrhythmia during treatment and the possibility of 
avoiding the use of local anesthetics associated to vaso-
constrictor agents (8). 
- Patients who have undergone heart transplantation: 
survival rate of these patients has increased remarkably 
with the introduction of immunosuppressive drugs such 
as cyclosporine. The side effects of such drugs include a 
high incidence of gingival hyperplasia. We must deter-
mine the correct dose of local anesthetic to be adminis-
tered to this type of patients (9). 
In line with different authors, we can state that in the 
case of healthy subjects the number of anesthetic car-
pules that can be administered is extrictly limited (15). 
Therefore, the greatest evidence so far reported on the 
effect of local anesthetic associated to vasoconstrictor 
agents used in dentistry on the cardiovascular system 
has been observed in healthy subjects (16). 
Nevertheless, the number of patients with cardiopathies 
who visit our clinics in increasing and the use of anes-
thetics associated to vasoconstrictor agents in this type 
of patients poses an interesting dichotomy. On the one 
hand, they imply greater safety and on the other hand 
their use may provoke cardiovascular complications. 
The aim of the present study is to search for and conduct 
a critical evaluation of recent reports on the effect and 
safety for the cardiovascular system of local anesthetics 
associated with vasoconstrictor agents used for dentistry 
in patients with cardiopathies. 
Material and Methods
We have searched for studies published in the last de-
cade (January 2000 through December 2010) which 
have been index-linked in Cochrane, Embase and Me-
dline, in the latter using the Pubmed search tool. 
We established the following search paremeters: ran-
domized controlled clinical trials conducted in humans 
without limit as regards age of male/female sex with any 
type of cardiopathy or cardiovascular disease written in 
English and Spanish and published in the last decade. 
The search words used were: vasoconstrictor agents, 
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Table 1. Results of search about clinical randomized trials in use of anesthetics associated to vasoconstrictors for dentistry in patients with 
cardiopathies.
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epinephrine/adverse effects, local anesthetics, dental 
restoration, oral surgery, cardiovascular diseases, coro-
nary arteriosclerosis, heart disease, hypertension, arr-
hythmias, coronariopathy, using the Boolean operator 
OR to combine search words. 
Finally, the results obtained were manually filtered rea-
ding the abstracts published in the above mentioned 
sources in order to subsequently obtain the original ver-
sion of the selected articles. 
Results
We have found six randomized clinical trials: Ezmek and 
colls. (2010), Elad and colls. (2008), Fernández-Cáceres 
and colls. (2008), Neves and colls. (2007), Conrado and 
colls. (2007), Meechan and colls. (2002) (9-14). These 
reports focus on different types of anesthetics: lidocaine 
2%, mepivacaine 2%, prilocaine 2% with or without as-
sociation to different concentrations of vasoconstrictor 
agents such as adrenaline or felypressin. 
The cardiopathies studied in the different trials range 
from hypertension to ischemic heart disease (stable an-
gina pectoris, myocardial infarction of more than 6 mon-
ths of evolution, coronary artery bypass of more than 3 
months of evolution, congestive heart failure) including 
arrhythmias, chronic coronary disease and heart trans-
plantation.
Table 1 shows the most significant information of the 
above mentioned six reports: study design (prospective 
randomized controlled), inclusion and exclusion criteria 
(differentiating diseases and their treatment), total num-
ber of patients (between 30 and 65), local anesthetics 
employed with or without association to vasoconstrictor 
agents and number of patients in each group, anesthetic 
dose (between 1 and 4 carpules of 1.8ml), parameters 
considered (ECG, BP and HR, in most cases), intervals 
and differences observed, if any.
Discussion
Epinephrine or adrenaline is one of the most widely used 
vasoconstrictor agents in association with local anesthe-
tics in dentistry. This substance provokes the constric-
tion of the blood vessels in the mucosa and skin, which 
favours latency period and reduces the dissemination of 
the local anesthetic due to the action of alpha-adrenergic 
receptors. But the β1-adrenergic receptors of epinephri-
ne will provoke an increase in heart rate and the β2-
adrenergic receptors will cause vasodilation in muscles 
and internal organs. However, only a few reports exist 
which relate the use of non-selective beta-adrenergic 
blocking agents and severe hypertensive side effects in 
dentistry (17).
A good number of publications assess the effects of di-
fferent anesthetics on certain cardiovascular parameters. 
Most of these reports have been carried out in healthy 
subjects and in general the alterations observed in para-
meters such as arterial tension (mainly), heart rate and 
others are not significant when comparing the use of 
anesthetics with and without vasoconstrictor agents. In 
these studies we observe a slight increase in the value 
of the above mentioned parameters which the authors 
usually attribute to the stress of the patients and to the 
rise in the levels of endogenous epinephrine or adrena-
line (18). 
The last systemic review of this subject, carried out by 
Bader and colls. in 2002 dealing with the cardiovascular 
effects of the use of epinephrine in dentistry in hyperten-
sive patients showed that neither systolic nor diastolic 
blood pressure increased, even in the case of non-con-
trolled patients (19). 
Since then, 6 other studies have been published which 
contribute level 1 evidence (randomized clinical trials) 
in this field of study. These studies have expanded their 
field of research to include patients with ischemic cardio-
pathies (stable angina pectoris, acute myocardial infarc-
tion, patients with bypass) as well as patients with heart 
transplantation or chronic coronary artery disease. As a 
result of these recent studies we are nowadays aware of 
the effect local anesthetics with or without association to 
vasoconstrictor agents have on a wider range of patholo-
gies related to the cardiovascular system.
The first conclusion we must mention is that in most of 
these studies we did not observe significant differences 
between patients with cardiopathies treated with anes-
thetics with or without association to vasoconstrictor 
agents, and when such differences were statistically de-
tected, the authors did not consider them critical from 
a clinical point of view (as is the case of the study by 
Meechan and colls. or Conrado and colls. (9, 14)). 
The anesthetics included in our study are widely used in 
dentistry (prilocaine, lidocaine, mepivacaine, articaine) 
in association or not with vasoconstrictor agents such 
as adrenaline or felypressin. This indicates that no new 
drugs have been introduced which could increase safety 
in their use with patients with cardiopathies.  The doses 
under study are similar to those administered to healthy 
subjects, so we must assume that in these studies local 
anesthetics are administered under normal conditions.
Although some studies report the use of invasive tech-
niques to control hemodynamic and cardiovascular va-
riables, the variables measured in the studies we have 
selected were arterial tension, heart rate, oxygen satura-
tion and the use of electrocardiogram (20). Only one of 
the studies searches for a possible cardiac damage not 
shown by means of these variables using other techni-
ques: biomarkers of myonecros, echocardiography or 
blood test (14). 
Generally, authors start to control these variables before 
the onset of treatment and finish once it has ended es-
tablishing three well differentiated periods (11): before 
treatment (baseline period) which in the reports under 
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study is set from 5-10 mins to 1 hr before treatment; 
during dental treatment; after dental treatment which 
may last from a few minutes after treatment up to 24 
hrs with a Holter. 50% of the studies analysed use this 
technique to carry out postoperative control of patients 
(12-14). The use of the Holter as well as a longer follow-
up period after injection of the anesthetic is thoroughly 
justified by the complexity of these patients and the risk 
of accident, even of a subclinical type (which we must 
detect) in the hours following the administration of the 
anesthesia. 
The exclusion criteria ban from the studies those pa-
tients with temporary conditions which contraindicate 
the use of the treatment (acute myocardial infarction 
of less than three or six months of evolution (11, 14)) 
or those with severe varieties of the pathologies under 
study (severe hypertension, class IV heart failure (10, 
12)). So far, there is no information available on the 
effects local anesthetics associated to vasoconstrictor 
agents may have on the cardiovascular system of these 
patients, therefore we must avoid their use, or be extre-
mely cautious in case of administration. In our opinion, 
such information is necessary and should be obtained by 
means of studies where patients, due to the complexity 
of their lesions and the risk of severe complications, are 
increasingly controlled and even hospitalized during the 
whole study period. 
Likewise, we cannot ignore the fact that the greater the 
complexity of the patients the wider the range of patho-
logies we will encounter and the greater the variety of 
drugs they will be administered. This in turn, can also 
provoke cardiovascular alterations in case of adminis-
tration of local anesthetics associated to vasoconstrictor 
agents (9). 
From the review of all the above mentioned studies we 
can conclude that in patients with cardiopathies (once 
we get over the period in which any type of dental ma-
nipulation is contraindicated) and in controlled hyper-
tensive patients, the use of local anesthetics associated 
to vasoconstrictor agents is justified. In any case, we 
must be very careful with the choice and execution of 
the anesthetic technique, being it possible to use a dose 
between 1.8 and 3.6 ml, on a general basis. Further stu-
dies are necessary to establish the effects of these drugs 
on severe hypertensive patients or in patients with other 
more advanced cardiopathies. 
References 
Taylor MB, Whitwam JG. The current status of pulse oximetry. 1. 
Clinical value of continuous noninvasive oxygen saturation moni-
toring. Anaesthesia. 1986;41:943-9.
Becker DE. Vasopressors in local anesthetics: controversies revisi-2. 
ted. J Tenn Dent Assoc: 1994;74:18-21.
Matsuura H. The systemic management of cardiovascular risk pa-3. 
tients in dentistry. Anesth Pain Control Dent. 1993;2:49-61.
Brown RS. Local anesthetics. Dent Clin North Am. 1994;38:619-4. 
32.
Yagiela JA, Haymore TL. Management of the hypertensive dental 5. 
patient. J Calif Dent Assoc. 2007;35:51-9.
Roberts HW, Mitnisky EF. Cardiac risk stratification for postmyo-6. 
cardial infarction dental patients. Oral Surg OralMed Oral Pathol 
Oral Radiol Endod 2001; 91:676-81.
Silvestre FJ. Manejo odontológico del paciente con cardiopatía is-7. 
quémica. Med Oral 2003;8:22-30.
Miller RA, Siegelman LI. Dental anesthestic management of a pa-8. 
tient with ventricular arrhytmias. Anesth Prog. 1998;45:68-73.
Meechan JG, Parry G, Rattray DT, Thomason JM. Effects of den-9. 
tal local anaesthetics in cardiac transplant recipients. Br Dent J. 
2002;192:161-3.
Ezmek B, Arslan A, Delilbasi C, Sencift K. Comparison of hemo-10. 
dynamic effects of lidocaine, prilocaine and mepivacaine solutions 
without vasoconstrictor in hypertensive patients. J Appl Oral Sci. 
2010;18:354-9. 
Elad S, Admon D, Kedmi M, Naveh E, Benzki E, Ayalon S et al. 11. 
The cardiovascular effect of local anesthesia with articaine plus 
1:200,000 adrenalin versus lidocaine plus 1:100,000 adrenalin in 
medically compromised cardiac patients: a prospective, randomi-
zed, double blinded study. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod. 2008;105:725-30.
Cáceres MT, Ludovice AC, Brito FS, Darrieux FC, Neves RS, 12. 
Scanavacca MI et al. Effects of local anesthesics with or without 
vasoconstrictor agent in patients with ventricular arrhythmias. Arq 
Bras Cariol. 2008;91:142-7.
Neves RS, Neves IL, Giorgi DM, Grupi CJ, César LA, Hueb W et 13. 
al. Effects of epinephrine in local anesthesia in patients with coro-
nary artery disease. Arq Bras Cardiol. 2007;51:434-40.
Conrado VS, de Andrade J, de Angelis GA, de Andrade AC, Ti-14. 
merman L, Andrade MM et al. Cardiovascular effects of local 
anethesia with vasocontrictor during dental extraction in coronary 
patients. Arq Bras Cardiol. 2007;88:507-13.
Subramaniam S, Tennant M. A concise review of the basic biology 15. 
and pharmacology of local analgesia. Aust Dent J. 2005;50: Suppl 
2 :S23-30.
Mason R, Drum M, Reader A, Nusstein J, Beck M.  A prospec-16. 
tive, randomized, double-blind comparison of 2% lidocaine with 
1:100,000 and 1:50,000 epinephrine and 3% mepivacaine for 
maxillary infiltrations. J Endod. 2009;35:1173–1177.
Hersh EV. Giannakopoulos H. Beta-adrenergic blocking agents and 17. 
dental vasoconstrictors. Dent Clin North Am. 2010;54:687-96.
Lipp M, Dick W, Daubländer M, Fuder H, Stanton-Hicks M. Exo-18. 
genous and endogenous plasma levels of epinephrine during dental 
treatment under local anesthesia. Reg Anesth. 1993; 18: 6-12.
Bader JD, Bonito AJ, Shugars DA. A systematic review of cardio-19. 
vascular effects of epinephrine on hypertensive dental patients. 
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:647-
53.
Hill CM, Mostafa P, Stuart AG, Thomas DW, Walker RV. ECG 20. 
variations in patients pre- and post-local anesthesia and analgesia. 
Br Dent J. 2009;207:E23.
